齐拉西酮和喹硫平对急性期精神分裂症的疗效和血浆非酶类抗氧化物水平的短期影响

目的比较齐拉西酮和喹硫平对首次住院精神分裂症患者的疗效及血浆非酶类抗氧化物水平的短期影响。方法 77例首次住院的精神分裂症患者按分层随机分成齐拉西酮组(n=39)和喹硫平组(n=38),齐拉西酮和喹硫平最低日剂量分别定为40 mg·d~(-1)和100 mg·d~(-1),最高日剂量分别限定为160 mg·d~(-1)和800 mg·d~(-1),每日分2次服用,治疗4周。以阳性症状与阴性症状量表(PANSS)评定疗效,检测患者治疗前后的血浆白蛋白、总胆红素及尿酸水平。结果治疗4周后,两组PANSS总分、阳性症状和阴性症状评分与治疗前相比均显著降低(P<0.05),组间均无显著差异(P>0.05)。齐拉西酮组和喹硫平组临床疗效比较无显著差异(67%vs.58%,P>0.05)。治疗4周后,两组血浆白蛋白、总胆红素水平组间均无显著差异(P>0.05),齐拉西酮组尿酸水平高于喹硫平组(P<0.05)。与治疗前相比,喹硫平组血浆白蛋白、总胆红素和尿酸水平均显著降低(P<0.05),齐拉西酮组与治疗前比较均无显著差异(P>0.05)。结论齐拉西酮和喹硫平对急性期精神分裂症的治疗均有效;齐拉西酮对氧化应激影响比喹硫平小,两药对血浆非酶类抗氧化系统的影响与临床疗效无关。

Study of ziprasidone and quetiapine on curative effect and short-term effect of plasma non-enzyme antioxidants levels in acute period patients with schizophrenia

AIM To compare the effects of ziprasidone and quetiapine on plasma non-enzyme antioxidants levels and their curative effects in the acute period hospitalization patients with schizophrenia.METHODS Totally 77 schizophrenic patients were randomly divided into ziprasidone(n = 39) and quetiapine(n = 38) group by stratified sampling for a four-week treatment.The initial doses was 40 mg·d~(-1) and 100 mg·d~(-1) and the highest dose did not exceed 160 mg·d~(-1) and 800 mg·d~(-1) for individual of the ziprasidone group and the quetiapine group respectively.The two groups were evaluated by the Positive and Negative Syndrome Scale (PANSS).Serum levels of albumins,uric acid,and bilirubin were tested.RESULTS After the four-week treatment,the PANSS scores,positive syndrome scores and negative syndrome scores in the two groups decreased compared with those before the treatment(P<0.05),with no differences between the two groups(P>0.05).There was no difference between the ziprasidone group and the quetiapine group about the effective rate (67%vs.58%,P>0.05).There were no differences between the two groups about the levels of albumins and bilirubin after the four-week treatment(P>0.05),and the levels of uric acid in the ziprasidone group were higher than those in the quetiapine group(P<0.05).The levels of albumins,bilirubin and uric acid in the quetiapine group were lower than those before the treatment(P<0.05),and there were no differences in the ziprasidone group(P>0.05).CONCLUSION Ziprasidone has the same curative effect as the quetiapine in the acute period patients with schizophrenia.Quetipine has more effects on oxidative stress than ziprasidone does. The effects of ziprasidone and quetiapine on the levels of plasma non - enzyme antioxidants have nothing to do with curative effects.